In pulmonary fibrosis, this unspecificity may even be favorable, since niclosamide co-inhibits several pathways (e.g., STAT3, AKT, and Wnt/β-catenin) which have been shown to contribute to fibrosis development. Here, AKT1 is linked to pulmonary fibrosis.